{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:52:22Z","timestamp":1775872342515,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    This case report describes a 51-year-old female with HER2-positive breast cancer who developed recurrent, severe thrombocytopenia during treatment with trastuzumab and pertuzumab. Through a retrospective analysis of her entire treatment course\u2014encompassing neoadjuvant, adjuvant, and radiotherapy phases\u2014we dynamically observed the temporal correlation between anti-HER2 therapy administration and acute drops in platelet count (nadir: 8\u00d710\n                    <jats:sup>9<\/jats:sup>\n                    \/L), accompanied by bleeding symptoms. The thrombocytopenia responded well to thrombopoietin-stimulating agents and immunomodulatory therapy but recurred persistently, even after switching to trastuzumab monotherapy or its subcutaneous formulation. Laboratory workup was notable for revealing a predisposition to undifferentiated connective tissue disease (UCTD) with positive antinuclear antibody (ANA) and positive anti-SSA\/Ro52 antibodies. Ultimately, all targeted therapies were discontinued due to intolerability. This case highlights that both trastuzumab and pertuzumab (including subcutaneous forms) can induce rare immune-mediated thrombocytopenia, a risk significantly heightened by underlying autoimmune serology. The mechanisms appear multifactorial, involving the patient\u2019s immune status, treatment phase, and route of administration. It underscores the need for heightened clinical vigilance, prompt drug suspension, supportive care, and individualized, multidisciplinary management in such scenarios.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1795252","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:32:14Z","timestamp":1773120734000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Recurrent severe thrombocytopenia induced by anti-HER2 therapy in a breast cancer patient with an underlying immune disorder: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Bo","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Liuyang People\u2019s Hospital","place":["Liuyang, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Liuyang People\u2019s Hospital","place":["Liuyang, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Liuyang People\u2019s Hospital","place":["Liuyang, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.3390\/cancers14143305","article-title":"Targeted therapeutic options and future perspectives for HER2-positive breast cancer","volume":"14","author":"Ferrando-D\u00edez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40779-022-00401-3","article-title":"The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer","volume":"9","author":"Sirhan","year":"2022","journal-title":"Mil Med Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/curroncol32080455","article-title":"Understanding chemotherapy-induced thrombocytopenia: implications for gastrointestinal cancer treatment","volume":"32","author":"Peshin","year":"2025","journal-title":"Curr Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20037","article-title":"Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment","volume":"206","author":"Song","year":"2025","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12885-023-10975-3","article-title":"Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia","volume":"23","author":"Shin","year":"2023","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40801-021-00278-z","article-title":"Adverse drug reactions with HER2-positive breast cancer treatment: an analysis from the italian pharmacovigilance database","volume":"9","author":"Barbieri","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21748","article-title":"Trastuzumab associated with recurrent severe thrombocytopenia and successful use of pertuzumab monotherapy","volume":"14","author":"Huff","year":"2022","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11926-023-01099-5","article-title":"Undifferentiated connective tissue disease: comprehensive review","volume":"25","author":"Rubio","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85620","article-title":"A rare case of crystal-storing histiocytosis of the breast in a patient with undifferentiated connective tissue disease","volume":"17","author":"Bedell","year":"2025","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12672-023-00616-3","article-title":"Chemotherapy-induced thrombocytopenia: literature review","volume":"14","author":"Gao","year":"2023","journal-title":"Discov Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13406","article-title":"Severe thrombocytopenia induced by trastuzumab rechallenge: a case report and literature review","volume":"46","author":"Wang","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12416","article-title":"Gradual thrombocytopenia induced by long-term trastuzumab exposure","volume":"41","author":"Miarons","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/1756-0500-6-400","article-title":"Severe thrombocytopenia after trastuzumab retreatment: a case report","volume":"6","author":"Pino","year":"2013","journal-title":"BMC Res Notes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.881838","article-title":"Severe thrombocytopenia related to trastuzumab infusion","volume":"17","author":"Mantzourani","year":"2011","journal-title":"Med Sci Monit"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.24920\/003799","article-title":"Trastuzumab-induced severe thrombocytopenia:A case report and literature review","volume":"35","author":"Zeng","year":"2020","journal-title":"Chin Med Sci J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000533234","article-title":"Immune dysfunction and infection - interaction between CLL and treatment: A reflection on current treatment paradigms and unmet needs","volume":"147","author":"Gargiulo","year":"2024","journal-title":"Acta Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1032225","article-title":"Case report: Identification of acute promyelocytic leukemia during osimertinib resistance followed by granulocyte colony-stimulating factor and pembrolizumab","volume":"12","author":"Tian","year":"2023","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2024.10.005","article-title":"A clinical review of subcutaneous trastuzumab and the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the treatment of HER2-positive breast cancer","volume":"25","author":"Ziegengeist","year":"2025","journal-title":"Clin Breast Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138-20220104-00009","article-title":"Standardized diagnosis and treatment of undifferentiated connective tissue disease and mixed connective tissue disease","volume":"61","author":"Mo","year":"2022","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2024.12.011","article-title":"Mixed and undifferentiated autoimmune connective tissue diseases","volume":"43","author":"Vesely","year":"2025","journal-title":"Clin Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17474086.2022.2082936","article-title":"Alternatives for managing patients with newly diagnosed immune thrombocytopenia: a narrative review","volume":"15","author":"G\u00f3mez-Almaguer","year":"2022","journal-title":"Expert Rev Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1795252\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:32:17Z","timestamp":1773120737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1795252\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1795252"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1795252","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1795252"}}